# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced one late-breaker oral platform presentation and two poster presentati...
In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide a...
JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ: ACAD) with a Overweight and lowers the price target...
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30 to ...
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales...
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the ef...